Identifying clinical risk factors of Clozapine-induced Neutropenia/Agranulocytosis
The use of clozapine to treat treatment-resistant schizophrenia is limited due to the occurrence of low white blood cells (neutropenia), and the rare but fatal adverse drug event of agranulocytosis. This study will examine clinical risk factors for neutropenia/agranulocytosis in patients treated with clozapine.